


## Patient derived orthotopic xenografts model from brain metastasis

LIDE provides an access to utilize patient-derived xenograft (PDX) generated from brain tumor lesion metastases from primary tumor to do orthotopic (PDOX) in vivo efficacy study.

Matching CR cells (CRCs) will be established based on corresponding PDX model, and such luciferase-labeled CRCs can be precisely injected into the brain using brain stereotaxic apparatus, followed by fluorescence tracking via IVIS as well as survival analysis.



Model ID	Source	CRCs	Luciferase labeling	In vivo evaluation
GL261	Murine glioblastoma cancer cell line	N/A	N/A	Completed
U87-MG	Human glioblastoma cancer cell line	N/A	Completed	Completed
U251	Human glioblastoma cancer cell line	N/A	Completed	TBD
LD1-0020-200615	Human glioblastoma PDX	Completed	Completed	Ongoing
LD1-2009-362263	Human breast cancer brain metastasis	Completed	Completed	Completed
LD1-2009-362541	Human breast cancer brain metastasis	Completed	Completed	Completed
LD1-2017-362457	Human gastric cancer brain metastasis	TBD	TBD	TBD
LD1-0011-362257	Human HCC brain metastatic PDX	TBD	TBD	TBD
LD1-2059-362445	Human NSCLC brain metastatic PDX	TBD	TBD	TBD

More models are coming soon...

# 1

## Case1: Tumor growth and survival in LD1-2009-362541-Luc PDX model






Image of mice tumor on brain orthotopic model (A, day 0; B, day 13; C, day 27.)



Tumor growth, body weight and survival of mice were observed after inoculation: A, tumor growth; B, survival curve; C, average body weight in mice during observation.

# 2

## Case2: Tumor growth and survival in LD1-2009-362263-Luc PDX model



Tumor size and survival of mice were observed after inoculation: Mice survival(A); tumor size(B) were measured by IVIS at 7 and 21 days after inoculation.